CD Skripsi
Angka kesintasan (survival rate) pasien kanker endometrium berdasarkan ekspresi reseptor estrogen
Endometrial cancer (EC) is a malignancy of the uterine epithelial lining with an increasing incidence and mortality rate, including in Indonesia. According to Bokhman's classification, endometrial cancer can be divided into two types: Type I, which is estrogen-dependent, and Type II, which is non-estrogen-dependent. The presence of estrogen hormone is known to influence patient prognosis through the effectiveness of hormonal therapy and may affect survival rates. This study aims to analyze survival rates, including Disease-Free Survival (DFS), Cancer-Specific Survival (CSS), and Overall Survival (OS) based on estrogen receptor (ER) expression in EC patients at Arifin Achmad Regional General Hospital, Riau Province. The study used Kaplan-Meier analysis with the Log-Rank test to determine differences in survival curves between groups, and the Cox regression test to determine the hazard ratio (HR). Data were obtained from 44 medical records of EC patients from 2019–2024 who met the inclusion criteria. Results showed that the majority of patients were over 50 years old (54.5%) with low-grade differentiation (86.4%), and 79.5% of patients had positive ER expression. The analysis of DFS, CSS, and OS in EC patients showed higher survival rates in the ER-positive group compared to the ER-negative group. In the CSS analysis, there was no significant difference in survival curves between the two ER expression groups (p-value = 0.125), with a hazard ratio for ER-negative patients of HR = 6.7 (95% CI = 0.41–110.5). However, in the DFS analysis, there was a significant difference in survival curves between the two ER expression groups (p-value = 0.027), with a hazard ratio for ER-negative patients of HR = 6.8 (95% CI = 0.95–49.05). In the OS analysis, there was no significant difference in survival curves was found between the two ER expression groups (p-value = 0.204), with a hazard ratio for ER-negative patients of HR = 2.2 (95% CI = 0.63–7.88). In conclusion, high ER expression is associated with better clinical outcomes in endometrial cancer patients, potentially influenced by the effectiveness of anti estrogen hormonal therapy.
Keywords: Cancer Specific Survival, Disease Free Survival, Endometrial Cancer, Estrogen Receptor, Overall Survival
Tidak tersedia versi lain